India's first intranasal Covid vaccine by Bharat Biotech gets DCGI approval
Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation.
Last month after completing the phase-III and booster dose trials for its intranasal Covid-19 vaccine, Bharat Biotech said it had conducted two separate trials for its intranasal Covid vaccine, one as a primary dose schedule and another as a booster dose, for subjects who have been double vaccinated with the two commonly administered Covid vaccines in India.
It has proven to be safe, well-tolerated and immunogenic in subjects in controlled trials, BBIL said in a statement. The data from both Phase III human clinical trials have been submitted for approval to national regulatory authorities, the company said. "If approved, this intranasal vaccine will make it easier to deploy in mass immunisation campaigns with an easy to administer formulation and delivery device.
Vectored vaccines also enable faster development of targeted vaccines in response to emerging variants of concern," Bharat Biotech joint managing director Suchhitra K Ella said.
United States
|
Cases: 46 252 513
Deaths: 750 423
Recovered: 0
|
India
|
Cases: 34 321 025
Deaths: 459 652
Recovered: 0
|
Brazil
|
Cases: 21 835 785
Deaths: 608 235
Recovered: 0
|
United Kingdom
|
Cases: 9 215 683
Deaths: 141 607
Recovered: 0
|
Russia
|
Cases: 8 494 589
Deaths: 237 619
Recovered: 0
|